This article was originally published in The Tan Sheet
Second quarter sales increased 8.7% to $76.7 mil. and net earnings grew 21.6% to $1.9 mil. Del's subsidiary, Del Pharmaceuticals, markets Orajel oral analgesics, Arthricare, Pronto, Tanac, Propa pH and the new Dermarest Psoriasis products. The OTC business reported a year-to-year increase in sales and income, according to the company. Del's sales for the first six months grew 8.9% to $144.1 mil. and earnings jumped 24.5% to $2.4 mil
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC